Sarah Rudder, PA
Physician Assistant · Lebanon, TNNPI 1669042230
Payments from drug & device makers
Across 134 payments — averaging $23.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Corcept Therapeutics$630
- Novo Nordisk$491
- Lilly USA, LLC$246
- Cequr Corporation$189
- BETA Bionics, Inc.$185
- Xeris Pharmaceuticals, Inc.$127
- plus $1K from 27 others
What the payments were for
- Food & beverage$3,094100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Corcept Therapeutics | 18 | $630 |
| Novo Nordisk | 24 | $491 |
| Lilly USA, LLC | 18 | $246 |
| Cequr Corporation | 2 | $189 |
| BETA Bionics, Inc. | 4 | $185 |
| Xeris Pharmaceuticals, Inc. | 5 | $127 |
| AbbVie | 5 | $106 |
| Boehringer Ingelheim | 5 | $88 |
| Insulet Corporation | 4 | $85 |
| Medtronic | 5 | $80 |
| AstraZeneca(2 entities) | 4 | $78 |
| Novartis | 5 | $77 |
| Sequel Med Tech, LLC | 3 | $70 |
| Mannkind Corporation | 3 | $61 |
| Dexcom, Inc. | 1 | $57 |
| Exact Sciences | 3 | $56 |
| Antares Pharma, Inc. | 3 | $51 |
| Astellas Pharma US Inc | 2 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $44 |
| Corium, LLC | 2 | $41 |
| Sumitomo Pharma America, Inc. | 2 | $37 |
| Sanofi-aventis U.S. LLC | 2 | $31 |
| IBSA Pharma Inc. | 2 | $30 |
| Tandem Diabetes Care, Inc. | 1 | $22 |
| Axsome Therapeutics, Inc. | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Amgen | 1 | $18 |
| Kyowa Kirin, Inc. | 1 | $17 |
| Madrigal Pharmaceuticals | 1 | $17 |
| Amphastar Pharmaceuticals, Inc. | 1 | $17 |
| Amneal Pharmaceuticals LLC | 1 | $17 |
| Ascendis Pharma Endocrinology Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Korlym$355
- CeQur Simplicity$173
- Ozempic$125
How this compares
$3,094 in reported general payments places this provider in the 85th percentile of 2,404 physician assistant providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 65 | $51,579 |
| OzempicSemaglutide | 40 | $41,016 |
| Tresiba Flextouch U-100Insulin Degludec | 62 | $36,289 |
| Tresiba Flextouch U-200Insulin Degludec | 26 | $21,775 |
| JanuviaSitagliptin Phosphate | 14 | $13,115 |
| Xigduo XrDapaglifloz Propaned/Metformin | 13 | $10,884 |
| FarxigaDapagliflozin Propanediol | 16 | $10,807 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 11 | $9,773 |
| Novolog FlexpenInsulin Aspart | 23 | $3,674 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 19 | $1,468 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $1,386 |
| SynthroidLevothyroxine Sodium | 14 | $1,037 |
| Methimazole | 40 | $337 |
| Pioglitazone Hcl | 24 | $239 |
| Rosuvastatin Calcium | 23 | $105 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $88 | $51,57965 claims |
| Novo NordiskOzempic | $491 | $41,01640 claims |
| AstraZenecaFarxiga | $78 | $10,80716 claims |
| AbbVieSynthroid | $106 | $1,03714 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $17 | $9326 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,404 physician assistant providers in Tennessee.
Other physician assistant in Lebanon
- Valerie OconnellLebanon$11K
- Lindsey NixKnoxville$576K
- Anna KerseySavannah$399K
- Jason HenryNashville$329K
- Brie ChandlerNashville$317K
- Loree EasleyBartlett$209K
- Katherine RunyanKnoxville$156K
- John KramerNashville$125K
- Robert LaughertyAlcoa$122K
- Elisabeth BennettNashville$109K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.